









Markets
/
Stocks
/
nasdaq-gral
/

Grail Inc

GRAL

86.360USD

+1.360+1.60%

Close 10/28, 16:00（ET）Quotes delayed by 15 min

3.11BMarket Cap

LossP/E TTM



Grail Inc

86.360

+1.360+1.60%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Grail Inc

Currency: USD Updated: 2025-10-28

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Grail Inc's Score

Industry at a Glance

Industry Ranking

76 / 391

Overall Ranking

182 / 4370

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Hold

Current Rating

61.500

Target Price

-27.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Grail Inc Highlights

StrengthsRisks

GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 126.09% year-on-year.

Undervalued

The company’s latest PE is -7.37, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 24.74M shares, decreasing 18.32% quarter-over-quarter.

Held by PRIMECAP Management

Star Investor PRIMECAP Management holds 2.05M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-28

The company's current financial score is 7.23, which is higher than the Biotechnology & Medical Research industry's average of 6.91. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 35.54M, representing a year-over-year increase of 11.18%, while its net profit experienced a year-over-year increase of 92.81%.

Score

Industry at a Glance

Previous score

7.23

Change



Financials

6.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.50

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Grail Inc's Company Valuation

Currency: USD Updated: 2025-10-28

The company’s current valuation score is 7.47, which is higher than the Biotechnology & Medical Research industry's average of 7.04. Its current P/E ratio is -7.37, which is -96.29% below the recent high of -0.27 and -6.36% above the recent low of -7.84.

Score

Industry at a Glance

Previous score

7.47

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/391

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-28

The company’s current earnings forecast score is 6.50, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Grail Inc is 61.50, with a high of 85.00 and a low of 38.00.

Score

Industry at a Glance

Previous score

6.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Hold

Current Rating

61.500

Target Price

-27.65%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

520

Total

Median

Average

Company name

Ratings

Analysts

Grail Inc

GRAL

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-28

The company’s current price momentum score is 9.15, which is higher than the Biotechnology & Medical Research industry's average of 6.74. Sideways: Currently, the stock price is trading between the resistance level at 106.74 and the support level at 62.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.13

Change

0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.095

Buy

RSI(14)

63.536

Neutral

STOCH(KDJ)(9,3,3)

45.996

Neutral

ATR(14)

9.411

High Vlolatility

CCI(14)

49.349

Neutral

Williams %R

44.103

Buy

TRIX(12,20)

2.498

Sell

StochRSI(14)

32.577

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

84.632

Buy

MA10

83.865

Buy

MA20

75.264

Buy

MA50

53.559

Buy

MA100

46.596

Buy

MA200

39.694

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-28

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 68.62%, representing a quarter-over-quarter decrease of 17.93%. The largest institutional shareholder is PRIMECAP Management, holding a total of 2.05M shares, representing 5.70% of shares outstanding, with 7.11% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Illumina Inc

4.50M

BlackRock Institutional Trust Company, N.A.

2.09M

+86.91%

PRIMECAP Management Company

Star Investors

2.05M

+0.13%

The Vanguard Group, Inc.

Star Investors

1.90M

+26.97%

CRCM L.P.

1.84M

-49.45%

Baker Bros. Advisors LP

1.63M

AQR Capital Management, LLC

1.33M

-0.49%

State Street Investment Management (US)

1.25M

-1.60%

Arbiter Partners Capital Management, LLC

1.04M

+1.25%

Sessa Capital

786.14K

-47.87%

Risk Assessment

Currency: USD Updated: 2025-10-28

The company’s current risk assessment score is 4.27, which is higher than the Biotechnology & Medical Research industry's average of 3.48. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.